The institute for evidence-based health and care management (I.f.G.V) is a private, independent interest-free and scientifically neutral institute.
Task of the I.f.G.V. is to accompany innovative medical and medical services, care programs, patient programs as well as innovative medical products and diagnostic approaches faster into the reimbursement systems of the complex German health system.
The I.f.G.V. works with his team of specialists according to strictly scientific and evidence-based criteria. A close network to politics, self-administration and funds supports us in the implementation and acceleration of the processes.
As partners, we do not leave our clients alone after the strategy has been determined. We accompany you from the first slide to the “signature”, through all instances and all authorities. We provide our personal (very close) contacts in the healthcare system.
If, in our opinion, a project has no prospect of success, we say so. We don’t want the client to sacrifice financial resources senselessly, and we don’t want to raise false hopes. This is how we work in a goal-oriented manner, based exclusively on a high scientific approach.
→ The diagnosis of alpha-1 antitrypsin deficiency (Rare disease according to OrphaNet) is a “discovery” for most patients after years of uncertainty. Since the main symptoms of alpha-1 antitrypsin deficiency also apply to other diseases such as COPD or asthma, many people do not recognize the disease for a long time.
Together with the Alpha1 Deutschland e.V. – Society for Alpha-1-Antitrypsin Deficiency sufferers, the I.f.G.V. Care solutions to improve patient care. Please read the joint position paper of Alpha 1 Gesellschaft and I.f.G.V. in our download area.
→ Flexible and individual reimbursement concepts are gaining more and more. important for high-cost products, medical devices, orphan drugs, biosimilars and products with a high supply need but “still” invalid medical data. Scientific based contracting is a possible approach that was developed with European payers and regulatory authorities. For example, scientific based contracting is used when entering the market early; but also as an early reimbursement concept based on certain criteria. For more information, see the article by Alexander Wilke MBA, LL.M. (Scientific director of I.f.G.V.) in the download area.
The I.f.G.V now on Medizintechnologie.de
Medizintechnologie.de is an initiative of the Federal Ministry of Education and Research (BMBF) and
supports medium-sized companies in the medical technology sector in particular in the innovation process.
The platform is based on the national strategy process “Innovations in Medical Technology”.
Akteursdatenbank – Institut für evidenzbasiertes Gesundheits- & Versorgungsmanagement, I.f.G.V. – Medizintechnologie
The increase in chronic diseases requires new innovative forms of care, especially against the background of demographic development.
Reimbursement by the statutory health insurance companies is a prerequisite for innovative services and methods developed by doctors to benefit the patient.
Not only disease-specific concepts may be taken into account, it is more about to maintain the quality of life and independence of the patients.
The I.f.G.V. supports you to present your projects in this context and to obtain valuable advice on solution and implementation.
Benefit Assessment Center
On request, we will accompany you from the clinical trial through all instances to the final reimbursement.